8-K - QCLS - Equibles

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CurrentReport

Pursuantto Section 13 or 15(d) of the

SecuritiesExchange Act of 1934

Dateof Report (Date of earliest event reported): June 30, 2021

MyMDPharmaceuticals, Inc.

(Exactname of Registrant as specified in its charter)

New Jersey	001-36268	22-2983783
(State or other jurisdiction<br><br> <br>of incorporation)	(Commission<br><br> <br>File No.)	(IRS Employer<br><br> <br>Identification No.)

MyMDPharmaceuticals, Inc.

855N. Wolfe Street, Suite 623

Baltimore,MD 21205

(Addressof principal executive offices and zip code)

Registrant’stelephone number, including area code: (856) 848-8698

(Formername or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
[ ]	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
[ ]	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Securities Registered pursuant to Section 12(b) of the Act:

Title<br> of each class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered
Common<br> stock, no par value per share	MYMD	The<br> NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements ofCertain Officers.

As previously reported, Ian Rhodes has served as the interim chief financial officer of MyMD Pharmaceuticals, Inc. (the “Company”) under a CFO Consulting Agreement, dated July 21, 2020, between the Company and Brio Financial Group. While the CFO Consulting Agreement expired on June 30, 2021, Mr. Rhodes will continue to serve as the Company’s interim chief financial officer under the same terms set forth in the CFO Consulting Agreement.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MyMD PHARMACEUTICALS, INC.
Date:<br> July 2, 2021	By:	/s/ Chris Chapman
		Chris<br> Chapman, M.D.
		President